TCS 359 is primarily used as a selective antagonist for the CB1 cannabinoid receptor, making it a valuable tool in neuroscience and pharmacological research. It is commonly applied in studies related to the endocannabinoid system, helping researchers investigate appetite regulation, metabolism, pain perception, and addiction mechanisms. Due to its selectivity, TCS 359 allows for targeted blockade of CB1 receptors without significant interaction with CB2 receptors, improving the accuracy of experimental results. It has also been used in preclinical models to explore potential treatments for obesity and substance use disorders by modulating cannabinoid signaling pathways. Its application supports the development and validation of new therapeutic agents targeting metabolic and neurological conditions.